Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS: In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity. RESULTS: A total of 432 patients underwent randomization to receive one of four doses of BIBF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo. In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 liters per year, as compared with 0.19 liters per year in the placebo group, a 68.4% reduction in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure). This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007). Gastrointestinal symptoms (which led to more discontinuations in the group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00514683 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Bayesian approach incorporated dynamic borrowing of historical placebo data from several external IPF trials, including the ASCEND, INPULSIS, and TOMORROW studies (Figures E2 and E3).2,3,13”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [13]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationBois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Self-citation
Cited by
Items 301–400 of 1,000
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
Lancaster, L., Goldin, J., Trampisch, M., Kim, G. H., Ilowite, J., Homik, L., Hotchkin, D. L., Kaye, M., Ryerson, C. J., Mogulkoc, N., et al. (2020) · The Open Respiratory Medicine Journal · doi:10.2174/1874306402014010022 · Cited by 48
Maher, T. M., Molyneaux, P. L., & Woodcock (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s38833 · Cited by 52
Cardiac manifestations of idiopathic pulmonary fibrosis
Agrawal, A., Verma, I., Shah, V., Agarwal, A., & Sikachi, R. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01023 · Cited by 50
Azuma, A., Taniguchi, H., Inoue, Y., Kondoh, Y., Ogura, T., Homma, S., Fujimoto, T., Sakamoto, W., Sugiyama, Y., & Nukiwa, T. (2017) · Respirology · doi:10.1111/resp.12960 · Cited by 46
Di Martino, E., Provenzani, A., Vitulo, P., & Polidori, P. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020964451 · Cited by 46
Interstitial Lung Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases
Rosas, I. O., Dellaripa, P. F., Lederer, D. J., Khanna, D., Young, L. R., & Martínez, F. J. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201312-429ld · Cited by 48
Therapeutic Approach to Adult Fibrotic Lung Diseases
Adegunsoye, A., & Strek, M. E. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.07.027 · Cited by 51
Otsubo, K., Kishimoto, J., Kenmotsu, H., Minegishi, Y., Ichihara, E., Shiraki, A., Kato, T., Atagi, S., Horinouchi, H., Ando, M., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.003 · Cited by 49
Barratt, S. L., Mulholland, S., Al Jbour, K., Steer, H., Gutsche, M., Foley, N., Srivastava, R., Sharp, C., & Adamali, H. I. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01480 · Cited by 43
Wollin, L., Distler, J. H. W., Denton, C. P., & Gahlemann, M. (2019) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319841842 · Cited by 47
Kreuter, M., Kögler, H., Trampisch, M., Geier, S., & Richeldi, L. (2019) · Respiratory Research · doi:10.1186/s12931-019-1037-7 · Cited by 48
Self-citationIdiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra
Rajagopal, K., Bryant, A. J., Sahay, S., Wareing, N. E., Zhou, Y., Pandit, L. M., & Karmouty‐Quintana, H. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15036 · Cited by 51
The Diagnosis and Treatment of Pulmonary Fibrosis
Kreuter, M., Müller-Ladner, U., Costabel, U., Jonigk, D. D., & Heußel, C. P. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0018 · Cited by 57
Self-citationThe tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease
Jamadar, A., Suma, S. M., Mathew, S., Fields, T. A., Wallace, D. P., Calvet, J. P., & Rao, R. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04248-9 · Cited by 50
Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis
Brown, K. K., Flaherty, K. R., Cottin, V., Raghu, G., Inoue, Y., Azuma, A., Huggins, J. T., Richeldi, L., Stowasser, S., Stansen, W., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.11.012 · Cited by 44
Self-citationNoth, I., Wijsenbeek, M. S., Kolb, M. R. J., Bonella, F., Moros, L., Wachtlin, D., & Corte, T. J. (2019) · European Respiratory Journal · doi:10.1183/13993003.01797-2018 · Cited by 47
Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice
Yilmaz, O., Öztay, F., & Kayalar, Ö. (2015) · Growth Factors · doi:10.3109/08977194.2015.1109511 · Cited by 46
Acute exacerbations in patients with idiopathic pulmonary fibrosis
Kim, D. W. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-86 · Cited by 48
Self-citationFerrara, G., Carlson, L., Palm, A., Einarsson, J., Olivesten, C., Sköld, M., & Pulmonar, F. T. S. I. (2016) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v3.31090 · Cited by 43
Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines
Чучалин, А. Г., Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Демура, Т. А., Ilkovich, M. M., Коган, Е. А., Samsonova, M. V., Speranskaya, A. A., Tyurin, I. E., et al. (2016) · PULMONOLOGIYA · doi:10.18093/0869-0189-2016-26-4-399-419 · Cited by 49
Treating Heart Failure with Preserved Ejection Fraction: Learning from Pulmonary Fibrosis
Graziani, F., Varone, F., Crea, F., & Richeldi, L. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1286 · Cited by 44
Self-citationSurber, M. W., Beck, S., Pham, S., Marsden, A. T., Gandi, S. K., Baily, J. E., & McElroy, M. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101938 · Cited by 45
Emerging strategies for treatment of systemic sclerosis
Khanna, D., Distler, J. H. W., Sandner, P., & Distler, O. (2016) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000207 · Cited by 47
Guidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis
Xaubet, A., Molina‐Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández‐Fabrellas, E., Rodríguez-Portal, J. A., Valenzuela, C., & Ancochea, J. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2017.03.001 · Cited by 48
Rozenberg, D., Sitzer, N., Porter, S., Weiss, A. J., Colman, R., Reid, W. D., Shapera, S., Fisher, J. H., & Wentlandt, K. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.12.364 · Cited by 43
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Lasky, J. A., Criner, G. J., Lazarus, H. M., KOHLBRENNER, V. M., Bender, S. D., & Richeldi, L. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01452-5 · Cited by 45
Self-citationPonatinib ameliorates pulmonary fibrosis by suppressing TGF-β1/Smad3 pathway
Qu, Y., Zhang, L., Kang, Z.-C., Jiang, W., & Lv, C. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.07.004 · Cited by 44
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
Azuma, A., Inomata, M., & Nishioka, Y. (2015) · Core evidence · doi:10.2147/ce.s82905 · Cited by 57
Novel drug targets for idiopathic pulmonary fibrosis
Sgalla, G., Cocconcelli, E., Tonelli, R., & Richeldi, L. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1152186 · Cited by 42
Self-citationNintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0418-6 · Cited by 49
Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis
King, C. S., & Nathan, S. D. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000190 · Cited by 44
The role of dimethylarginine dimethylaminohydrolase ( DDAH ) in pulmonary fibrosis
Janssen, W., Pullamsetti, S. S., Cooke, J. P., Weißmann, N., Günther, A., & SCHERMULY, R. T. (2012) · The Journal of Pathology · doi:10.1002/path.4127 · Cited by 49
Leppäranta, O., Tikkanen, J., Bespalov, M. M., Koli, K. M., & Myllärniemi, M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0201oc · Cited by 46
The big clinical trials in idiopathic pulmonary fibrosis
Luppi, F., Spagnolo, P., Cerri, S., & Richeldi, L. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283567ff9 · Cited by 42
Self-citationCapdevila, J., Carrato, A., Tabernero, J. M., & Grande, E. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.05.004 · Cited by 43
Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications
Spagnolo, P., Rossi, G., & Cavazza, A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.917050 · Cited by 47
Liang, J., Cao, H., Yang, Y., Ke, Y., Yu, Y., Sun, C., Yue, L., & Lin, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.626953 · Cited by 50
Kewalramani, N., Machahua, C., Poletti, V. E., Cadranel, J. L., Wells, A. U., & Funke-Chambour, M. (2022) · ERJ Open Research · doi:10.1183/23120541.00115-2022 · Cited by 45
Raghu, G. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1842ed · Cited by 42
Self-citationA novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung
Matsuhira, T., Nishiyama, O., Tabata, Y., Kaji, C., Kubota-Ishida, N., Chiba, Y., Sano, H., Iwanaga, T., & Tohda, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173508 · Cited by 41
Hong, S., Lu, Y., Chen, S.-Y., Hsu, C.-F., Lu, Y.-C., Wang, C., & Huang, K. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05876-z · Cited by 42
Ando, K., Sekiya, M., Tobino, K., & Takahashi, K. (2013) · Lung · doi:10.1007/s00408-013-9513-1 · Cited by 41
Aiello, M., Bertorelli, G., Bocchino, M., Chetta, A. A., Fiore-Donati, A., Fois, A. G., Marinari, S., Oggionni, T., Polla, B., Rosi, E., et al. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.02.005 · Cited by 46
Graney, B. A., & Lee, J. S. (2018) · Patient Related Outcome Measures · doi:10.2147/prom.s144425 · Cited by 42
Lee, S. H., Yeo, Y., Kim, T., Lee, H. L., Lee, J. H., Park, Y. B., Park, J. S., Kim, Y. H., Song, J. W., Jhun, B. W., et al. (2019) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2018.0091 · Cited by 49
Self-citationTherapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies
Lescoat, A., Roofeh, D., Kuwana, M., Lafyatis, R., Allanore, Y., & Khanna, D. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08891-0 · Cited by 41
Pharmacological management of IPF
Borie, R., Justet, A., Beltramo, G., Manali, E. D., Pradère, P., Spagnolo, P., & Crestani, B. (2016) · Respirology · doi:10.1111/resp.12778 · Cited by 42
Lederer, D. J., Bradford, W. Z., Fagan, E., Glaspole, I., Glassberg, M. K., Glasscock, K., Kardatzke, D. R., King, T. E., LANCASTER, L. H., Nathan, S. D., et al. (2015) · CHEST Journal · doi:10.1378/chest.14-2817 · Cited by 40
Self-citationThe role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
Cottin, V. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-s1-s5 · Cited by 47
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations
Nakamura, Y., & Suda, T. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s39897 · Cited by 49
Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
Case, A. H., & Johnson, P. (2017) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2017-000192 · Cited by 46
Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma
Kurimoto, R., Ebata, T., Iwasawa, S., Ishiwata, T., Tada, Y., Tatsumi, K., & Takiguchi, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6188 · Cited by 42
The clinical impact of major comorbidities on idiopathic pulmonary fibrosis
Suzuki, A., & Kondoh, Y. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2016.11.004 · Cited by 46
Dai, W., Qiu, J. Y., Sun, J. P., Ma, C., Huang, N., Jiang, Y., Zeng, J., Ren, B., Li, W., & Li, Y. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26961 · Cited by 43
Shaish, H. A., Ahmed, F. S., Lederer, D. J., D’Souza, B. M., Armenta, P. M., Salvatore, M. M., Saqi, A., Huang, S., Jambawalikar, S., & Mutasa, S. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202001-068oc · Cited by 40
Shen, H., Zhang, N., Liu, Y., Yang, X., He, Y., Li, Q., Shen, X., Zhu, Y., & Yang, Y. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.805535 · Cited by 42
Mochizuka, Y., Suzuki, Y., Kono, M., Hasegawa, H., Hashimoto, D., Yokomura, K., Inoue, Y., Yasui, H., Hozumi, H., Karayama, M., et al. (2023) · Respirology · doi:10.1111/resp.14523 · Cited by 41
Hoppo, T., Komatsu, Y., & Jobe, B. A. (2012) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2012.01446.x · Cited by 40
Update on diagnosis and treatment of idiopathic pulmonary fibrosis
Martínez, J. A. B., Baldi, B. G., da Costa, C. H., Jezler, S. F. D. O., Lima, M. S., & Rufino, R. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000000152 · Cited by 43
Ikemori, R., Gabasa, M., Duch, P., Vizoso, M., Bragado, P., Arshakyan, M., Luis, I.-C., Marín, A., Morán, S., de Moura, M. C., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0637 · Cited by 41
Podolanczuk, A. J., & Cottin, V. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02454-9 · Cited by 45
Severe idiopathic pulmonary fibrosis: what can be done?
Caminati, A., Cassandro, R., Torre, O., & Harari, S. A. (2017) · European Respiratory Review · doi:10.1183/16000617.0047-2017 · Cited by 39
Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis
Schmid, U., Döge, C., Dallinger, C., & Freiwald, M. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.11.004 · Cited by 38
Loveman, E., Copley, V. R., Colquitt, J. L., Scott, D. A., Clegg, A. J., Jones, J., O’Reilly, K. M., Singh, S., Bausewein, C., & Wells, A. U. (2015) · Health Technology Assessment · doi:10.3310/hta19200 · Cited by 41
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Rinciog, C., Watkins, M., Chang, S., Maher, T. M., LeReun, C., Esser, D., & Diamantopoulos, A. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0480-2 · Cited by 39
Tsai, M., Chang, W., Liao, S., Chang, K., Sheu, C., & Kuo, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081958 · Cited by 42
Glaspole, I., Bonella, F., Bargagli, E., Glassberg, M. K., Caro, F. M., Stansen, W., Quaresma, M., Orsatti, L., & Bendstrup, E. M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01695-y · Cited by 43
The Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
Behr, J. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0875 · Cited by 44
Biologic Treatments in Interstitial Lung Diseases
Karampitsakos, Τ., Vraka, A., Bouros, D. E., Liossis, S. C., & Τzouvelekis, Α. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00041 · Cited by 38
Lynch, J. P., Fishbein, M. C., Saggar, R., Zisman, D. A., & Belperio, J. A. (2007) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.1.3.377 · Cited by 37
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis
Rimner, A., Moore, Z., Lobaugh, S. M., Geyer, A. I., Gelblum, D. Y., Abdulnour, R.-E. E., Shepherd, A. F., Shaverdian, N., Wu, A. J.-C., Cuaron, J. J., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.02.030 · Cited by 39
New perspectives on management of idiopathic pulmonary fibrosis
Puglisi, S., Torrisi, S. E., Vindigni, V., Giuliano, R., Palmucci, S., Mulè, M., & Vancheri, C. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315624276 · Cited by 38
S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017
Behr, J., Günther, A., Bonella, F., Geissler, K. H., Koschel, D., Kreuter, M., Prasse, A., Schönfeld, N., Sitter, H., Müller–Quernheim, J., et al. (2017) · Pneumologie · doi:10.1055/s-0043-106160 · Cited by 37
Self-citationCrișan-Dabija, R. A., Pavel, C.-A., Popa, I. V., Țăruș, A., & Burlacu, A. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00387 · Cited by 37
Chu, K.-A., Yeh, C., Kuo, F.-H., Lin, W.-R., Hsu, C.-W., Chen, T.-H., & Fu, Y.-S. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02012-y · Cited by 38
Türkkan, G., Willems, Y. C. P., Hendriks, L. E. L., Mostard, R. L. M., Conemans, L. H., Gietema, H. A., Mitea, C., Peeters, S., & Ruysscher, D. D. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.11.020 · Cited by 38
Roberts, M. J., May, L. T., Keen, A. C., Liu, B., Lam, T., Charlton, S. J., Rosethorne, E. M., & Halls, M. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.669227 · Cited by 37
Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis
Maher, T. M., Stowasser, S., Voß, F., Bendstrup, E. M., Kreuter, M., Martínez, F. J., Sime, P. J., & Stock, C. (2023) · Respirology · doi:10.1111/resp.14579 · Cited by 35
Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group
Sköld, C. M., Bendstrup, E. M., Myllärniemi, M., Guðmundsson, G., Sjåheim, T., Hilberg, O., Altraja, A., Kaarteenaho, R. L., & Ferrara, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12571 · Cited by 38
Nintedanib for Idiopathic Pulmonary Fibrosis
Tepede, A. K., & Yogaratnam, D. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017735242 · Cited by 40
Roberts, M. J., Broome, R., Kent, T. C., Charlton, S. J., & Rosethorne, E. M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0759-2 · Cited by 38
Torrisi, S. E., Kahn, N. C., Wälscher, J., Sarmand, N., Polke, M., Kehler, L., Eichinger, M., Heußel, C. P., Palmucci, S., Sambataro, F. M., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0937-0 · Cited by 35
Zulfikar, S., Mulholland, S., Adamali, H. I., & Barratt, S. L. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s228362 · Cited by 41
Shumar, J. N., Chandel, A., & King, C. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112285 · Cited by 37
Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis
Glasgow, C. G., El‐Chemaly, S., & Moss, J. (2012) · European Respiratory Review · doi:10.1183/09059180.00009311 · Cited by 37
Combinatorial Pharmacophore-Based 3D-QSAR Analysis and Virtual Screening of FGFR1 Inhibitors
Zhou, N., Xu, Y., Liu, X., Wang, Y., Peng, J., Luo, X., Zheng, M., Chen, K., & Jiang, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160613407 · Cited by 34
Jaguin, M., Fardel, O., & Lecureur, V. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.04.007 · Cited by 35
Togami, K., Yamaguchi, K., Chono, S., & Tada, H. (2017) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2017.02.023 · Cited by 34
Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences
Harari, S. A., & Caminati, A. (2015) · European Respiratory Review · doi:10.1183/16000617.0042-2015 · Cited by 36
Kim, H.-Y., Kim, M., Kim, S., Joen, D., & Lee, K. (2018) · Molecules · doi:10.3390/molecules23081974 · Cited by 37
Effects of Nintedanib in an Animal Model of Liver Fibrosis
Wollin, L., Togbe, D., & Ryffel, B. (2020) · BioMed Research International · doi:10.1155/2020/3867198 · Cited by 37
Kerget, B., Çil, G., Araz, Ö., Alper, F., & Akgün, M. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2022.12.021 · Cited by 40
Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity
Tai, W., Shiau, C., Li, Y.-S., Chang, C.-W., Huang, J., Hsueh, T.-T., Yu, H.-C., & Chen, K. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.017 · Cited by 34
Fala, L. (2015) · PubMed · Cited by 33
Zolak, J. S., & de Andrade, J. A. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.08.006 · Cited by 38
Liang, M., Matteson, E. L., Abril, A., & Distler, J. H. W. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221074457 · Cited by 34
Hoffmann‐Vold, A., Volkmann, E. R., Allanore, Y., Assassi, S., Vries-Bouwstra, J. K. D., Smith, V. M., Tschoepe, I., Loaiza, L., Kanakapura, M., & Distler, O. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00215-6 · Cited by 34
Aschner, Y., Khalifah, A. P., Briones, N. J., Yamashita, C. M., Dolgonos, L., Young, S. K., Campbell, M., Riches, D. W. H., Redente, E. F., Janssen, W. J., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.01.016 · Cited by 34
Acute exacerbations complicating interstitial lung disease
Ryerson, C. J., & Collard, H. R. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000073 · Cited by 32
Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis
Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Ilkovich, M. M., Коган, Е. А., Мержоева, З. М., Petrov, D., Samsonova, M. V., Terpigorev, S. A., Трушенко, Н. В., et al. (2022) · PULMONOLOGIYA · doi:10.18093/0869-0189-2022-32-3-473-495 · Cited by 32
Metadata
- Authors
- Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klüglich, M., & du Bois, R. M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Ruhrlandklinik (DE)
- Asan Medical Center (KR)
- Royal Brompton Hospital (GB)
- Michigan Medicine (US)
- Duke Medical Center (US)
- University of Washington (US)
- Boehringer Ingelheim (France) (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1079-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152974152
- Cited by
- 1,157
- References
- 22
- Citations by year
- 2026: 32 · 2025: 50 · 2024: 79 · 2023: 74 · 2022: 83 · 2021: 86 · 2020: 73 · 2019: 72 · 2018: 91 · 2017: 102 · 2016: 88 · 2015: 100 · 2014: 71 · 2013: 80 · 2012: 61
- FWCI
- 60.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, tyrosine kinase inhibitors, forced vital capacity decline, lung fibrosis progression, acute exacerbation, quality of life, gastrointestinal adverse effects, liver aminotransferases, dose comparison, St George's Respiratory Questionnaire, total lung capacity, drug safety and efficacy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Enzyme Inhibitors, Female, Humans, Indoles, Liver, Male, Middle Aged, Protein-Tyrosine Kinases, Vital Capacity, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.